With the emergency use authorization has been granted for ‘Evusheld Inj,’ the first-ever preventive antibody therapy for COVID-19 in Korea, the drug is expected to be used in immunocompromised patients who are unlikely to mount an adequate response to COVID-19 vaccinations.

The Ministry of Food and Drug Safety (Minister: Yu-Kyoung Oh) announced on the 30th that the ministry decided to grant emergency use authorization for 20,000 courses of the antibody therapy ‘Evusheld Inj (tixagevimab, cilgavimab) that was developed by AstraZeneca to prevent COVID-19 infections.

The authorization was made after deliberation by the Medical Product Safety Management and Supply Committee for Public Hea